Search
Oct 1
Mathai Mammen provides an update on the latest at FogPharma, and his philosophy of following the cadence of science, not the calendar
The Chairman and CEO of FogPharma describes the progress the company has made this year, including on the lead β-catenin/TCF4 inhibitor...
Feb 28
Mathai Mammen on being back to company building at Fog Pharma
He describes how Fog is leveraging the way α-helices mediate interactions with other proteins to solve the undruggable problem.